Mizuho raised the firm’s price target on Inspire Medical (INSP) to $130 from $110 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector,” the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target raised to $118 from $82 at JPMorgan
- Oppenheimer upgrades Inspire Medical to Outperform on CMS blunder
- Inspire Medical upgraded to Outperform from Perform at Oppenheimer
- Inspire Medical price target raised to $165 from $135 at Piper Sandler
- Inspire Medical price target raised to $180 from $125 at Baird